We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock
FRTX

Delisted

FRTX was delisted on the 18th of December, 2023.

Back to rankings

30 hedge funds and large institutions have $2.74M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 3

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

11% more funds holding

Funds holding: 27 → 30 (+3)

50% less capital invested

Capital invested by funds: $5.53M → $2.74M (-$2.79M)

Holders
30
Holders Change
+3
Holders Change %
+11.11%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TI
Telemetry Investments
New York
+$732K
2
Renaissance Technologies
Renaissance Technologies
New York
+$661K
3
VF
Virtu Financial
New York
+$88.3K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$70.5K
5
BlackRock
BlackRock
New York
+$60.7K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$179K
2
SSWM
Smith Salley Wealth Management
North Carolina
-$32K
3
Morgan Stanley
Morgan Stanley
New York
-$29.2K
4
Fifth Third Bancorp
Fifth Third Bancorp
Ohio
-$18K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$9.07K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$695K +$661K +36,833 +120%
Vanguard Group
2
Vanguard Group
Pennsylvania
$621K -$9.07K -505 -0.8%
TI
3
Telemetry Investments
New York
$580K +$732K +40,747 +262%
PCM
4
Palisade Capital Management
New Jersey
$218K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$143K – – –
Two Sigma Advisers
6
Two Sigma Advisers
New York
$97K +$70.5K +3,925 +72%
VF
7
Virtu Financial
New York
$51K +$88.3K +4,916 New
Thrivent Financial for Lutherans
8
Thrivent Financial for Lutherans
Minnesota
$50K – – –
BlackRock
9
BlackRock
New York
$49K +$60.7K +3,381 +239%
Citadel Advisors
10
Citadel Advisors
Florida
$39K +$35.5K +1,978 +112%
Northern Trust
11
Northern Trust
Illinois
$27K – – –
Two Sigma Investments
12
Two Sigma Investments
New York
$24K +$6.27K +349 +17%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$24K +$41.9K +2,332 New
JSW
14
Journey Strategic Wealth
New Jersey
$24K +$41.9K +2,334 New
WIC
15
Water Island Capital
New York
$23K +$39.9K +2,222 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$14K – – –
State Street
17
State Street
Massachusetts
$14K – – –
Millennium Management
18
Millennium Management
New York
$11K +$19.1K +1,061 New
SPIA
19
Steward Partners Investment Advisory
New York
$8K – – –
TRCT
20
Tower Research Capital (TRC)
New York
$8K +$11.1K +619 +302%
UBS Group
21
UBS Group
Switzerland
$7K +$4.22K +235 +50%
Victory Capital Management
22
Victory Capital Management
Texas
$4K +$1.4K +78 +29%
HF
23
HRT Financial
New York
$4K +$6.97K +388 New
CA
24
Cetera Advisors
Colorado
$2K -$3.99K -222 -50%
NFG
25
Next Financial Group
Texas
$1K – – –
1
2

FRTX Hedge Fund Activity: Q4 2021 in Review

30 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2021, worth a combined $2.74M — down 50% from $5.53M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new FRTX positions and 4 closed out — a net gain of 3 holders — while 10 added to existing stakes and 3 trimmed.

The largest buyer was Telemetry Investments, adding an estimated $732K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $179K sold.

  • 30 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2021, up from 27 in Q3 2021.
  • Funds reported $2.74M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2021, down 50% quarter-over-quarter.
  • 7 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +3 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2021 was Telemetry Investments, an estimated $732K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2021 was GSA Capital Partners, an estimated $179K sold.

Based on aggregated 13F filings for Q4 2021.